<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(2)</volume><submitter>Ata F</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Insulin-like growth factor-2 (IGF-2)-mediated hypoglycemia is a rare yet clinically significant entity with considerable morbidity and mortality. Existing literature is limited and fails to offer a comprehensive understanding of its clinical trajectory, management and prognostication.&lt;h4>Methods&lt;/h4>Systematic review of English-language articles reporting primary patient data on IMH was searched using electronic databases (PubMed, Scopus and Embase) from any date up to 21 December 2022. Data were analysed in STATA-16.&lt;h4>Results&lt;/h4>The systematic review contains 172 studies, including 1 Randomised controlled trial, 1 prospective observational study, 5 retrospective observational studies, 150 case reports, 11 case series and 4 conference abstracts. A total of 233 patie</pubmed_abstract><journal>Endocrinology, diabetes &amp; metabolism</journal><pagination>e00471</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10897872</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A systematic review of literature on Insulin-like growth factor-2-mediated hypoglycaemia in non-islet cell tumours.</pubmed_title><pmcid>PMC10897872</pmcid><pubmed_authors>Khamees I</pubmed_authors><pubmed_authors>Malkawi L</pubmed_authors><pubmed_authors>Khan AA</pubmed_authors><pubmed_authors>Aljaloudi E</pubmed_authors><pubmed_authors>Mohamed A</pubmed_authors><pubmed_authors>Al-Sadi A</pubmed_authors><pubmed_authors>Anum</pubmed_authors><pubmed_authors>Choudry H</pubmed_authors><pubmed_authors>Ata F</pubmed_authors></additional><is_claimable>false</is_claimable><name>A systematic review of literature on Insulin-like growth factor-2-mediated hypoglycaemia in non-islet cell tumours.</name><description>&lt;h4>Introduction&lt;/h4>Insulin-like growth factor-2 (IGF-2)-mediated hypoglycemia is a rare yet clinically significant entity with considerable morbidity and mortality. Existing literature is limited and fails to offer a comprehensive understanding of its clinical trajectory, management and prognostication.&lt;h4>Methods&lt;/h4>Systematic review of English-language articles reporting primary patient data on IMH was searched using electronic databases (PubMed, Scopus and Embase) from any date up to 21 December 2022. Data were analysed in STATA-16.&lt;h4>Results&lt;/h4>The systematic review contains 172 studies, including 1 Randomised controlled trial, 1 prospective observational study, 5 retrospective observational studies, 150 case reports, 11 case series and 4 conference abstracts. A total of 233 patie</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-05-29T20:27:12.571Z</modification><creation>2024-11-07T01:00:48.566Z</creation></dates><accession>S-EPMC10897872</accession><cross_references><pubmed>38411039</pubmed><doi>10.1002/edm2.471</doi></cross_references></HashMap>